Replimune pulls in $55 mln Series B

UK-based Replimune, a developer of oncolytic immunotherapy, has closed $55 million in Series B financing. Foresite Capital led the round with participation from other investors that included Bain Capital Life Sciences, Redmile Group, Cormorant Asset Management, Leerink Partners, Atlas Venture, Forbion Capital Partners and Omega Funds. In addition to the funding, Dr. Brett Zbar of Foresite Capital and Dr. Kapil Dhingr, the former head of clinical oncology at Roche, will join Replimune’s board of directors.

Source: Press Release